Genetic method for diagnosis and treatment of pre and post coronavirus infections
AssigneeGeneticure Inc.
InventorsEric Snyder, Scott C. Snyder, Ryan Sprissler
Life of this patent
Estimating the term…
Loading patent…
AssigneeGeneticure Inc.
InventorsEric Snyder, Scott C. Snyder, Ryan Sprissler
Estimating the term…
The present invention is directed to management of coronavirus exposure and/or infection by analyzing a patients 21 SNPs of the patients AGT, renin, AT1R, ACE, ADRB1 and ACE2 genes arnd use of the analysis to determine which pharmaceutical compound(s) associated with treatment of the RAAS system issues should be administered and/or discontinued, if any, to ameliorate the potential for coronavirus infection and/or the severity of coronavirus infection. Typical coronaviruses to be treated include SARS coronavirus, MERS coronavirus and/or Covid-19 coronavirus. Co-administration of anti-viral, quinoline-like and/or quinone-like drugs and ACE2 agonists are also disclosed.
A method comprising treating a person who is exposed to a coronavirus but is not yet infected with the coronavirus, comprising administering one or more pharmaceutical compounds that lowers ACE2 levels according to one of Pre-infection protocol 1-6 and the person's genotype for a series of 21 single nucleotide polymorphisms (SNPs) recited below as rs numbers with variable nucleotides indicated in parenthesis:
A method for treating a patient who is infected with a coronavirus, comprising administering one or more pharmaceutical compounds that increase ACE2 levels according to one of Post-infection protocols 1-6 and the person's genotype for a series of 21 single nucleotide polymorphisms (SNPs) recited below as rs numbers with variable nucleotides indicated in parenthesis:
Dependencies are inferred from the claim text.